TX-EAGLE-EYE-NETWORKS
Eagle Eye Networks, the global leader in cloud video surveillance, today announced the acquisition of artificial intelligence leader Uncanny Vision, accelerating the company’s leadership in providing AI and analytics to make customers’ businesses more efficient and the world a safer place. The acquisition also includes research and development capabilities and a new regional office in Bangalore, India.
“After evaluating more than a dozen AI companies, we began working with Uncanny Vision in 2020. It didn’t take long for us to conclude that Uncanny Vision is the clear leader in surveillance AI,” said Dean Drako, Eagle Eye Networks CEO. “Their award-winning AI technology is deployed across thousands of locations, including Fortune 500 customers.”
The deal accelerates Eagle Eye’s plan, announced in November 2020 , when Eagle Eye raised funds from venture capital firm Accel, to dramatically reshape video surveillance.
Uncanny Vision’s deep learning algorithms enable recognition, identification, and prediction, improving business operations, customer service, and site safety. Uncanny Vision’s award-winning AI is used today in multiple applications, including:
- Smart parking
- Retail analytics
- Gate security
- Toll automation
- Smart cities
- ATM monitoring
- Worker safety
- Perimeter security
Drako said, “Uncanny Vision’s tools for training, building, and optimizing models, and its infrastructure for managing and storing training data are superior. This is a key component we’re excited to add to the Eagle Eye Networks platform.”
All 60 Uncanny Vision employees will be retained, and Eagle Eye plans to expand the Bangalore office. Eagle Eye is committed to supporting Uncanny Vision’s current customers, and will continue to build its global infrastructure to provide the very best 24/7 support to its valued customers around the world.
Uncanny Vision co-founders, Ranjith Parakkal and Navaneethan Sundaramoorthy, have joined the Eagle Eye leadership team. Parakkal said, “We share the Eagle Eye team’s vision to deliver advanced, cyber secure AI cloud video surveillance offerings that transform video surveillance for businesses around the globe.”
"The economic model of delivering subscription-based AI on a per-camera basis through a global cloud infrastructure will ignite growth for security integrators who are otherwise challenged with how to build a financially stable business," said Alper Cetingok, Managing Director and Head of the Security & Safety Practice at Raymond James.[1]
ABOUT EAGLE EYE NETWORKS
Eagle Eye Networks is No. 1 in cloud video surveillance worldwide. Our 100% cloud managed solutions provide cloud and on-premises recording, bank-level security and encryption, and broad analog and digital camera support – all accessed via the web or mobile applications. Eagle Eye Networks delivers cyber secure cloud-based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. All products benefit from Eagle Eye’s developer friendly RESTful API platform and Big Data Video FrameworkTM . Headquartered in Austin, Texas, Eagle Eye has offices in Bangalore, Tokyo, and Amsterdam. For more information, visit www.een.com .
ABOUT UNCANNY VISION
Founded in 2013, Uncanny Vision is an award-winning AI-based computer vision company delivering next generation intelligent surveillance solutions for smart cities, smart buildings and infrastructure specifically for people and vehicle monitoring using cameras. Uncanny Vision surveillance enables cameras to "see" and "understand" their environment instantly, using optimized real-time AI/deep learning algorithms. For more information, visit www.uncannyvision.com .
[1] Raymond James & Associates was not a party to the transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005143/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom